EmilyHsiehMD
Pediatric Hematology & Oncology • Los Angeles, CAPediatric Hematologic Oncology
Pediatric Transplantation & Cellular Therapy Physician, Children's Hospital Los Angeles Assistant Professor, Keck Medicine of USC
Dr. Hsieh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4650 Sunset Blvd
MS #54
Los Angeles, CA 90027Phone+1 323-361-8687- Is this information wrong?
Summary
- Dr. Emily Hsieh is a pediatric hematologist/oncologist in Los Angeles, CA and is affiliated with Children's Hospital Los Angeles. She specializes in transplantation and cellular therapy with a focus on hematologic malignancies, pediatric hematopoietic stem cell transplantation, adoptive immunotherapy, and chimeric antigen receptor (CAR) T-cell therapy. Her research interests include developing CAR T-cell therapies for hematologic and solid malignancies, as well as evaluating delayed and late effects of CAR T-cell therapy.
Education & Training
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2017 - 2020
Tufts Medical CenterChief Residency, Pediatrics, 2016 - 2017- Tufts Medical CenterResidency, Pediatrics, 2013 - 2016
Duke-NUS Graduate Medical School SingaporeClass of 2013, MD
Certifications & Licensure
TX State Medical License 2020 - 2025
CA State Medical License 2021 - 2025
MA State Medical License 2016 - 2024- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma Start of enrollment: 2020 Sep 25
- A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia Start of enrollment: 2017 Nov 03
- Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2020 Jan 08
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsINSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.Emily M Hsieh, Haneen Shalabi, Rebecca Epperly, Pamela L Wolters, Joshua A Hill, Rebecca Gardner, Aimee C Talleur, Nirali N Shah, Jenna Rossoff, McNerney, K.> ;Transplantation and Cellular Therapy. 2024 Jan 1
- 2 citationsChimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.Elizabeth M Holland, Bonnie Yates, Seth M Steinberg, Constance M Yuan, Hao-Wei Wang, Colleen Annesley, Haneen Shalabi, David Stroncek, Terry J Fry, Joerg Krueger, Elad...> ;Transplantation and Cellular Therapy. 2023 Sep 1
- 6 citationsLow rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.Emily M Hsieh, Regina M Myers, Bonnie Yates, Colleen Annesley, Samuel John, Agne Taraseviciute, Seth M Steinberg, Jennifer Sheppard, Perry Chung, Lee Chen, Daniel W Le...> ;Blood Advances. 2022 Sep 13
- Join now to see all
Hospital Affiliations
Children's Hospital Los AngelesLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
